“ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING”, Mediterr J Hematol Infect Dis, vol. 10, no. 1, p. e2018014, Feb. 2018, doi: 10.4084/mjhid.2018.014.